Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
ViewRay Systems, Inc. is a private technology company seeking to provide the global radiation therapy community with advanced medical instruments incorporating the highest level of technology possible. Our belief is that only significant technological innovation can enable society to conquer disease. Our mission is to dare to change the paradigms of medicine and solve “impossible” technical problems to enable clinicians to effect a cure to save precious human lives, mitigate pain and suffering, and enhance quality of life. Our vision is to become the world’s leader in producing highly effective innovative technology to cure cancer.
ViewRay Systems designs, manufactures, and markets the MRIdian A3i® radiation therapy system to treat cancer patients with the smallest radiation therapy margins availablei with the highest patient throughput demonstrated for the most complicated casesii The system treats by aligning the sharpest radiation therapy beam on the market to diagnostic quality magnetic resonance images (MRIs) of the patient, adapts the treatment plan to the reality of the patient, and then uses the real-time MRIs to control the beam and record real-time doses delivered to the patient.
ViewRay Systems, Inc. is looking for a Technical Writer that shares our passion for conquering cancer and help us support radiation therapy systems worldwide. The ideal candidate shares enthusiasm for engaging in the best business practices while improving cancer therapy. You will be assisting with radiation therapy user manuals & documentation.
Job Type: Full-time
Work Location: In person in Cleveland, OH: Relocate before starting work
Salary: Commensurate with experience
Paid time off
ViewRay Systems, Inc. is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, creed, national origin, gender, age, sexual orientation, status as a protected disabled or Vietnam Era Veteran, disability, or any other legally protected status.
Reference: https://jamanetwork.com/journals/jamaoncology/fullarticle/2800541